1Department of Biosciences, Veer Narmad South Gujarat University, Surat, India
2Shree Ramkrishna Institute of Computer Education and Applied Sciences, Sarvajanik University, Surat, India
© 2026 Korea Disease Control and Prevention Agency.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ethics Approval
Not applicable.
Conflicts of Interest
The authors have no conflicts of interest to declare.
Funding
This research was funded by the Gujarat State Biotechnology Mission (GSBTM) under the “Network Program on Antimicrobial Resistance, Superbugs, and One Health” project (No. GSBTM/JD(R&D)/616/21-22/1236) for the 2021–22 financial year. The authors acknowledge the invaluable support provided by GSBTM throughout this project.
Availability of Data
The datasets generated during and/or analyzed during this study are available in the supplementary file.
Authors’ Contributions
Conceptualization: SA, RP, PD; Data curation: SA, NV, AV, AG; Formal analysis: SA, KA, NV, AV; Funding acquisition: RP, PD; Investigation: SA, KA, NV, AV; Methodology: SA, KA, NV, AV; Project administration: RP, PD; Resources: RP, PD; Supervision: RP, PD; Visualization: SA, NV, AV, AG; Writing–original draft: SA; Writing–review & editing: all authors. All authors read and approved the final manuscript.
Acknowledgements
This study was conducted under the “Network Program on Antimicrobial Resistance, Superbugs, and One Health” project (No. GSBTM/JD(R&D)/616/21-22/1236), under the Research Support Scheme 2021–22 of the Gujarat State Biotechnology Mission, Gandhinagar, India. The authors sincerely thank the Bioinformatics and Supercomputer Lab at the Department of Biosciences, Veer Narmad South Gujarat University, for providing computational resources and technical assistance.
Additional Contributions
Artificial intelligence-assisted tools, including Gemini and Grammarly, were used to refine the English language, punctuation, and reference formatting. The authors reviewed and edited the output and take full responsibility for the content of the publication.
| No. | Antimicrobial class | Subclass/Category Code | Antimicrobial agent | Disc abbreviation used | Disc concentration |
|---|---|---|---|---|---|
| 1 | Penicillin | Aminopenicillin (PEN) | Ampicillin | AMP | 10 µg |
| Aminopenicillin+β-lactamase inhibitor (PEN+INH) | Amoxicillin/clavulanic acid | AMC | 30 µg | ||
| Penicillinase-stable penicillin | Oxacillin | OX | 1 µg | ||
| 2 | β-lactam/β-lactamase inhibitor combination | β-lactam/β-lactamase inhibitor combination (BL+INH) | Cefotaxime/clavulanic acid | CEC | 30/10 µg |
| Ceftazidime/clavulanic acid | CAC | 30/10 µg | |||
| Piperacillin/tazobactam | PIT | 100/10 µg | |||
| Ticarcillin/clavulanic acid | TCC | 75/10 µg | |||
| 3 | Cephalosporin | First-generation cephalosporin (CEPH1) | Cefazolin | CZ | 30 µg |
| Cephalothin | CEP | 30 µg | |||
| Second-generation cephalosporin (CEPH2) | Cefuroxime | CFM | 5 µg | ||
| Third-generation cephalosporin (CEPH3) | Cefotaxime | CTX | 30 µg | ||
| Ceftazidime | CAZ | 30 µg | |||
| Fourth-generation cephalosporin (CEPH4) | Ceftriaxone | CTR | 30 µg | ||
| Cefepime | CPM | 30 µg | |||
| Cephamycin | Cefoxitin | CX | 30 µg | ||
| 4 | Penems | Carbapenem | Imipenem | IPM | 10 µg |
| Ertapenem | ETP | 10 µg | |||
| Meropenem | MRP | 10 µg | |||
| 5 | Aminoglycoside | Aminoglycoside | Gentamicin | GEN | 10 µg |
| Netilmicin | NET | 30 µg | |||
| Amikacin | AK | 30 µg | |||
| Tobramycin | TOB | 10 µg | |||
| 6 | Quinolone | Fluoroquinolones | Ciprofloxacin | CIP | 30 µg |
| Ofloxacin | OF | 5 µg | |||
| Norfloxacin | NX | 10 µg | |||
| Pefloxacin | PF | 5 µg | |||
| Quinolone | Nalidixic acid | NA | 30 µg | ||
| 7 | Nitroheterocyclics | Nitroheterocyclics | Nitrofurantoin | NIT | 300 µg |
| 8 | Folate pathway antagonists | Folate pathway antagonist combination | Cotrimoxazole | COT | 25 µg |
| 9 | Phenicol | Phenicols | Chloramphenicol | C | 30 µg |
| 10 | Tetracycline | Tetracycline | Minocycline | MI | 30 µg |
| Tetracycline | TE | 30 µg | |||
| Doxycycline hydrochloride | DO | 30 µg | |||
| Tetracycline/glycylcycline (GLY) | Tigecycline | TGC | 15 µg | ||
| 11 | Macrolides | Macrolide | Erythromycin | E | 15 µg |
| Azithromycin | AZM | 15 µg | |||
| 12 | Oxazolidinone | Oxazolidinone | Linezolid | LZ | 30 µg |
| Lincosamides | Lincosamide | Clindamycin | CD | 2 µg | |
| 13 | Fosfomycin | Fosfomycin | Fosfomycin | FO | 50 µg |
| 14 | Lipopeptides | Polymyxins | Colistin | CS | 10 µg |
| Polymyxin B | PB | 300 units | |||
| 15 | Monobactam | Monobactam | Aztreonam | AT | 30 µg |
| 16 | Glycopeptides | Glycopeptides | Vancomycin | VA | 30 µg |
| Lipoglycopeptides | Teicoplanin | TEI | 30 µg |
| No. | Antimicrobial class | Subclass/Category Code | Antimicrobial agent | Disc abbreviation used | Disc concentration |
|---|---|---|---|---|---|
| 1 | Penicillin | Aminopenicillin (PEN) | Ampicillin | AMP | 10 µg |
| Aminopenicillin+β-lactamase inhibitor (PEN+INH) | Amoxicillin/clavulanic acid | AMC | 30 µg | ||
| Penicillinase-stable penicillin | Oxacillin | OX | 1 µg | ||
| 2 | β-lactam/β-lactamase inhibitor combination | β-lactam/β-lactamase inhibitor combination (BL+INH) | Cefotaxime/clavulanic acid | CEC | 30/10 µg |
| Ceftazidime/clavulanic acid | CAC | 30/10 µg | |||
| Piperacillin/tazobactam | PIT | 100/10 µg | |||
| Ticarcillin/clavulanic acid | TCC | 75/10 µg | |||
| 3 | Cephalosporin | First-generation cephalosporin (CEPH1) | Cefazolin | CZ | 30 µg |
| Cephalothin | CEP | 30 µg | |||
| Second-generation cephalosporin (CEPH2) | Cefuroxime | CFM | 5 µg | ||
| Third-generation cephalosporin (CEPH3) | Cefotaxime | CTX | 30 µg | ||
| Ceftazidime | CAZ | 30 µg | |||
| Fourth-generation cephalosporin (CEPH4) | Ceftriaxone | CTR | 30 µg | ||
| Cefepime | CPM | 30 µg | |||
| Cephamycin | Cefoxitin | CX | 30 µg | ||
| 4 | Penems | Carbapenem | Imipenem | IPM | 10 µg |
| Ertapenem | ETP | 10 µg | |||
| Meropenem | MRP | 10 µg | |||
| 5 | Aminoglycoside | Aminoglycoside | Gentamicin | GEN | 10 µg |
| Netilmicin | NET | 30 µg | |||
| Amikacin | AK | 30 µg | |||
| Tobramycin | TOB | 10 µg | |||
| 6 | Quinolone | Fluoroquinolones | Ciprofloxacin | CIP | 30 µg |
| Ofloxacin | OF | 5 µg | |||
| Norfloxacin | NX | 10 µg | |||
| Pefloxacin | PF | 5 µg | |||
| Quinolone | Nalidixic acid | NA | 30 µg | ||
| 7 | Nitroheterocyclics | Nitroheterocyclics | Nitrofurantoin | NIT | 300 µg |
| 8 | Folate pathway antagonists | Folate pathway antagonist combination | Cotrimoxazole | COT | 25 µg |
| 9 | Phenicol | Phenicols | Chloramphenicol | C | 30 µg |
| 10 | Tetracycline | Tetracycline | Minocycline | MI | 30 µg |
| Tetracycline | TE | 30 µg | |||
| Doxycycline hydrochloride | DO | 30 µg | |||
| Tetracycline/glycylcycline (GLY) | Tigecycline | TGC | 15 µg | ||
| 11 | Macrolides | Macrolide | Erythromycin | E | 15 µg |
| Azithromycin | AZM | 15 µg | |||
| 12 | Oxazolidinone | Oxazolidinone | Linezolid | LZ | 30 µg |
| Lincosamides | Lincosamide | Clindamycin | CD | 2 µg | |
| 13 | Fosfomycin | Fosfomycin | Fosfomycin | FO | 50 µg |
| 14 | Lipopeptides | Polymyxins | Colistin | CS | 10 µg |
| Polymyxin B | PB | 300 units | |||
| 15 | Monobactam | Monobactam | Aztreonam | AT | 30 µg |
| 16 | Glycopeptides | Glycopeptides | Vancomycin | VA | 30 µg |
| Lipoglycopeptides | Teicoplanin | TEI | 30 µg |